MMP9 and B-cell chronic lymphocytic leukemia: Anyway, HPF, besides showing anti-angiogenic activity, inhibits the MMP-9 production in B-CLL [192] and prevents the formation of microtubules in bone marrow endothelial cells, so that its therapeutic use in B-CLL patients has been suggested [192].